VRTX - Vertex Pharmaceuticals Incorporated

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Currency in USD

Valuation measures4

Market cap (intra-day) 89.65B
Enterprise value 80.03B
Trailing P/E 27.74
Forward P/E 25.13
PEG Ratio (5 yr expected) 0.56
Price/sales (ttm)9.82
Price/book (mrq)6.21
Enterprise value/revenue 8.69
Enterprise value/EBITDA 18.31

Trading information

Stock price history

Beta (5Y monthly) 0.49
52-week change 319.82%
S&P500 52-week change 30.07%
52-week high 3354.46
52-week low 3243.17
50-day moving average 3330.24
200-day moving average 3306.63

Share statistics

Avg vol (3-month) 31.18M
Avg vol (10-day) 31.74M
Shares outstanding 5257.55M
Implied shares outstanding 6N/A
Float 8256.9M
% held by insiders 10.16%
% held by institutions 195.88%
Shares short (14 May 2023) 43.23M
Short ratio (14 May 2023) 42.94
Short % of float (14 May 2023) 41.25%
Short % of shares outstanding (14 May 2023) 41.25%
Shares short (prior month 13 Apr 2023) 43.38M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 22:1
Last split date 323 Aug 2000

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)30 Mar 2023


Profit margin 35.40%
Operating margin (ttm)48.51%

Management effectiveness

Return on assets (ttm)16.80%
Return on equity (ttm)25.73%

Income statement

Revenue (ttm)9.21B
Revenue per share (ttm)35.87
Quarterly revenue growth (yoy)13.20%
Gross profit (ttm)5.32B
Net income avi to common (ttm)3.26B
Diluted EPS (ttm)12.36
Quarterly earnings growth (yoy)-8.20%

Balance sheet

Total cash (mrq)10.41B
Total cash per share (mrq)40.44
Total debt (mrq)789.2M
Total debt/equity (mrq)5.47
Current ratio (mrq)4.28
Book value per share (mrq)56.05

Cash flow statement

Operating cash flow (ttm)4.07B
Levered free cash flow (ttm)3.63B